FINWIRES · TerminalLIVE
FINWIRES

午間要聞:AMD第一季財報與第二季業績指引皆超乎預期;英偉達與康寧達成多年商業與技術合作協議

By

-- 週三上午交易時段,美國三大股指均上漲超過1%,投資人對美伊即將達成結束戰爭的協議表示樂觀。 公司新聞方面,AMD(Advanced Micro Devices)週二晚間公佈了第一季調整後每股收益為1.37美元,高於去年同期的0.96美元,也高於FactSet分析師一致預期的1.29美元。第一季營收為102.5億美元,高於去年同期的74.4億美元,也高於FactSet一致預期的99億美元。該公司預計第二季營收為112億美元,上下浮動3億美元,高於FactSet一致預期的105.4億美元。 AMD股價在午盤前後上漲了17.7%。 英偉達(Nvidia,NVDA)和康寧(Corning,GLW)週三宣布,雙方已達成一項多年商業和技術合作協議,旨在擴大美國先進光連接技術的製造規模,以支持人工智慧基礎設施建設。根據合作協議,康寧公司將把在美國的光技術產能提高10倍,並將其在美國的光纖產能提高50%以上。康寧公司週三向美國證券交易委員會(SEC)提交的文件顯示,為配合此次合作,該公司已向英偉達出售認股權證,允許英偉達以每股180美元的行權價格購買至多1500萬股康寧普通股。康寧公司也表示,英偉達也獲得了預付認股權證,允許英偉達以每股0.0001美元的行使價格購買至多300萬股康寧普通股,總購買價格為5億美元。英偉達股價上漲5.2%,康寧股價上漲13.8%。 優步科技(Uber Technologies,股票代號:UBER)週三公佈了第一季非GAAP每股收益,為0.72美元,高於去年同期的0.50美元,也高於FactSet預測的0.69美元。 Uber(Uber)第一季營收為132億美元,高於去年同期的115.3億美元,也高於FactSet預期的132.8億美元。優步預計第二季非GAAP每股盈餘為0.78美元至0.82美元,高於FactSet預期的0.79美元。該公司預計第二季總預訂金額為562.5億美元至577.5億美元,高於FactSet預期的561.7億美元。優步股價上漲8.2%。 迪士尼(DIS)週三公佈了第二財季調整後每股收益為1.57美元,高於去年同期的1.45美元,也高於FactSet預期的1.49美元。第二財季營收為251.7億美元,高於去年同期的236.2億美元,也高於FactSet預期的248.7億美元。該公司表示,預計2026財年調整後每股盈餘將成長約12%,不計入第53週的影響。迪士尼股價上漲超過6%。 IBM(IBM)週三表示,正與Oracle(ORCL)合作,將Watsonx的強大功能引入Oracle雲端基礎設施(OCI),以期「提升企業多智能體、人工智慧驅動的生產力和效率」。該公司表示,Watsonx Orchesstrate AI智能體產品將於7月在OCI上線。 IBM股價下跌0.9%,而Oracle股價上漲1.9%。

Price: $416.71, Change: $+61.45, Percent Change: +17.30%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL